Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Sickle Cell Disease Clinical Trial

— SCD-CARRE  

Official title:

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04084080
• Other study ID #: STUDY20110362
• Secondary ID: UG3HL143192
• Status: Recruiting
• Phase: Phase 3
• Start date: February 26, 2020
• Est. completion date: April 30, 2026

Study information

• Verified date: December 2023
• Source: University of Pittsburgh
• Contact: Jude Jonassaint, RN
• Phone: 919-219-7481
• Email: jonas[@]pitt.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

Description:

As patients with sickle cell disease (SCD) live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive events take their toll, with the progressive development of cardiopulmonary organ dysfunction. This culminates in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, chronic kidney disease and sudden death, all major cardiovascular complications of SCD for which there are no approved or consensus therapies. The risk of having pulmonary hypertension and diastolic heart disease can be non-invasively assessed by laboratory tests (NT-proBNP) and Doppler-echocardiography (estimated pulmonary artery systolic pressure). A recent meta-analysis of approximately 6000 patients with SCD demonstrated that patients with elevated tricuspid regurgitant jet velocity (TRV), which is an Doppler-echocardiographic measurement that estimates the pulmonary artery systolic pressure, walked an estimated 30.4 meters less in a 6 minute walk test than those without elevated TRV, and elevated TRV was associated with high mortality (hazard ratio of 4.9). In two large registry cohorts of adult patients with SCD, the investigators found that approximately 20% of the adult SCD population have high values for both biomarkers, defined as a TRV ≥ 2.5 meters per second AND a NT-proBNP ≥ 160 pg/mL, and that the 12-month mortality rate is 7.9% in this group as compared to 0.5% in patients with normal TRV or NT-proBNP values, with a risk ratio for hospitalization of 1.6. This suggests that a simple screening profile of TRV and NT-proBNP can identify about 20% of patients with SCD at the highest risk of death and hospitalization.

Given the increased mortality and early loss of functional capacity associated with cardiovascular disease in SCD adults, it is important to test effective therapeutic interventions in such patients. Red blood cell transfusions are administered by either simple or exchange transfusion, the latter removes the patients blood and replaces it with transfused red blood cells. Exchange transfusions have proven effective for acute treatment of almost all SCD complications, including severe acute chest syndrome, stroke, splenic or hepatic sequestration, and multi-organ failure, and are also used chronically for stroke prevention and recurrent acute chest syndrome. In this study the investigators hypothesize that monthly exchange transfusion will limit disease progression, improve exercise capacity, and prevent interval episodes of vaso-occlusive painful crisis and the acute chest syndrome that acutely increases pulmonary pressures and cause right heart failure.

The investigators propose to perform a clinical trial to evaluate the effects of automated exchange blood transfusion on patient morbidity and mortality, compared to standard of care among 150 adult high risk SCD patients. The trial will leverage existing coordinating center infrastructure at the University of Pittsburgh and will involve 22 experienced clinical sites. Despite the safety and wide utilization of erythrocytapheresis in adult patients with SCD, there is no consensus or quality efficacy data on its use to improve outcomes in our aging high-risk SCD patients with progressive end-organ dysfunction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: April 30, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Diagnosis of SCD: homozygous sickle cell disease, hemoglobin-SC, Sß-thalassemia, hemoglobin-SO or hemoglobin-SD.

• Patients not on a chronic exchange transfusion program for at least 60 days.

• If patients are on a SCD drug (e.g. hydroxyurea, glutamine, or P-selectin inhibitors), the doses must be stable for at least 60 days prior to randomization.

• Any one of the following vasculopathy biomarker clinical results (a, b, c, d or e) measured in the last 24 months before randomization that indicates a high-risk patient:

1. Both a TRV 2.5- <3.0 m/sec and NT-proBNP plasma level = 160 pg/mL,

2. TRV = 3.0 m/sec,

3. Both a mean pulmonary artery pressure (PAP) by right heart catheterization 20-24 mmHg and NT-proBNP plasma level = 160 pg/mL,

4. Mean PAP by right heart catheterization = 25 mmHg,

5. Chronic kidney disease (CKD) due to SCD with abnormal measures on 2 separate occasions as defined by: macroalbuminuria (albumin to creatinine ratio (ACR) >300 mg/g) or proteinuria (protein to creatinine ratio >30 mg/mmol), or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. (It is recommended that local laboratories use Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation without ethnic factors when estimating and reporting GFR).

Clinical results of these biomarkers measured locally at sites within 24 months prior to randomization are acceptable to determine eligibility. TRV, PAP, NT-proBNP, albumin to creatinine ratio, protein to creatinine ratio, or eGFR values must be measured in a steady state (defined as measured = 14 days since an acute care pain event) on different days.

vi. Written informed consent obtained from patient to participate in the trial.

Exclusion Criteria:

• RBC alloimmunization resulting in inability of blood bank to obtain compatible components for chronic exchange transfusions

• Previous history of hyper-hemolysis syndrome

• Previous history of severe transfusion reaction resulting in renal failure or due to serious complications such as hypotension or respiratory distress

• More than 10 vaso-occlusive episodes in the past 12 months requiring admission to a hospital to receive treatment.

• Religious objection to receiving blood transfusion

• Diagnosis of ischemic stroke within the past 6 months

• Clinical evidence of liver failure or advanced cirrhosis or any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the trial

• Women of childbearing potential who have a positive pregnancy test at baseline

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Biological:
• Red Blood Cell
Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.

Other:
• Standard of care
NHLBI/ASH/ATS Expert Panel recommended guidelines

Locations

Country	Name	City	State
Brazil	Hemorio	Rio De Janeiro
France	Kremlin-Bicêtre	Créteil
France	Henri Mondor Hopital	Paris
United States	Emory University	Atlanta	Georgia
United States	Johns Hopkins University	Baltimore	Maryland
United States	University of Maryland	Baltimore	Maryland
United States	Boston Medical Center	Boston	Massachusetts
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	Atrium Health	Charlotte	North Carolina
United States	University of Illinois at Chicago	Chicago	Illinois
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Ohio State University	Columbus	Ohio
United States	Duke University	Durham	North Carolina
United States	East Carolina University	Greenville	North Carolina
United States	University of Texas Health Science Center at Houston	Houston	Texas
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Montefiore Medical Center	New York	New York
United States	UCSF Benioff Children's Hospital Oakland	Oakland	California
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Virginia Commonwealth University	Richmond	Virginia
United States	Washington University-St. Louis	Saint Louis	Missouri
United States	University of Alabama	Tuscaloosa	Alabama
United States	Howard University Center for Sickle Cell Disease	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Gladwin, Mark, MD	National Heart, Lung, and Blood Institute (NHLBI)

Countries where clinical trial is conducted

United States,  Brazil,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Episodes of clinical worsening	The efficacy of the intervention will be measured by comparing the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 13 months between groups.	13 months
Secondary	Acute healthcare event	A 6-level prioritized rank-based outcome: 1.No death or SCD-related acute health care encounters (SCDAcuteE) within (w/in) 13 months (m) of randomization; 2. Had SCDAcuteE but NO major complications (acute kidney injury (AKI), acute chest syndrome (ACS), cor pulmonale, stroke, liver failure) associated with an SCDAcuteE nor death w/in 13 m of randomization; 3. Had 1 major complication (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with an SCDAcuteE but not death w/in 13 m of randomization; 4. Had 2 major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with SCDAcuteE but not death w/in 13 m of randomization; 5. Had = 3 major complications (AKI, ACS, cor pulmonale, stroke, or liver failure) associated with SCDAcuteE but not death w/in 13 m of randomization; 6.Death w/in 13 m of randomization. If the same complication reoccurs, occurrences will be counted as separate complications if the acute health care encounters are separated by =7 days.	13 months
Secondary	Twelve-month survival	Survival over thirteen-month period will be analyzed and compared between the group receiving the intervention and the group receiving care routinely provided for sickle cell patients based on the NHLBI guidelines.	13 months
Secondary	Survival free of acute healthcare encounters	Survival free of acute health care encounters over 13 months.	13 months
Secondary	Total number of acute health care encounters	The total number of acute health care encounters (non-elective infusion center/ER/Hospital visits) with evidence of cor pulmonale (physical exam findings, NT-proBNP increase plus echocardiographic evidence of worsening right heart function).	13 months
Secondary	Measures of exercise capacity - 6 minute walk distance	Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in the six minute walk distance assessment	4, 8, and 12 months
Secondary	Measures of exercise capacity - outpatient activity	Measures of exercise capacity assessed at 4, 8 and 12 months by the distance walked in a 7 day in the outpatient setting.	4, 8, and 12 months
Secondary	Cardiovascular risk	Established cardiovascular risk biomarkers and indices are combined to help the investigators form an opinion about cardiovascular risks. The following will be measured: NT-proBNP, QT prolongation, systemic pulse pressure, albuminuria, estimated GFR and CKD progression Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group criteria.	12 months
Secondary	Development of new leg ulcers	Participants will be assessed for development of new leg ulcers at each physical exam.	4, 8 and 12 months
Secondary	Measures of exercise capacity - WHO Classification	WHO functional status severity will be measured assessing by looking at limitation of usual physical activity from I (no limitation in usual physical activity) to Class IV (inability to perform any physical activity at rest)	4, 8 and 12 months
Secondary	Nocturnal desaturation	Nocturnal desaturation will measured using a wearable device to measure blood oxygen saturation for 7 nights at home.	4, 8 and 12 months
Secondary	SCD specific patient reported outcomes - Pain	SCD specific patient reported outcomes as measured by self-reported pain	4, 8 and 12 months
Secondary	SCD specific patient reported outcomes -Quality of Life modified PROMIS scale	SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from PROMIS QoL measure	4, 8 and 12 months
Secondary	SCD specific patient reported outcomes -Quality of Life modified ASCQ-Me scale	SCD specific patient reported outcomes as measured by a modified version of health related quality of life questionnaire from ASCQ-Me QoL measure	4, 8 and 12 months
Secondary	Cardiovascular function by echocardiography - TRV	Cardiovascular function measures from echocardiography assessed at 4, 8 and 12 months: echocardiographic measures of tricuspid regurgitant jet velocity in m/s.	4, 8 and 12 months
Secondary	Cardiovascular function by echocardiography - diastolic left heart function	Diastolic left heart function measured by E/A ratio, E/Em ratio, and deceleration times will be assessed by echocardiography.	4, 8 and 12 months
Secondary	Cardiovascular function by echocardiography - systolic right heart function	Systolic right heart health will be measured by assessing tricuspid annular plane systolic excursion (TAPSE), right ventricular size and contractility from echocardiography of the heart.	4, 8 and 12 months